Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780 as it tries to narrow a lead held by MSD with its rival cholesterol drug.